Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: February 3, 2011
Last updated: June 7, 2013
Last verified: June 2013

The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.

Essential Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of SO in newly diagnosed hypertensive patients [ Time Frame: Visit 1-3: heart rate & Blood pressure, treatment presribed by physician. The interval between visit 1 and visit 2 is upto 4 weeks and interval between visit 2 & visit 3 is upto 4 weeks depending on Investigators discretion. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Association of SO and heart rate. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]
  • Subjective symptoms noticed by the doctor. [ Time Frame: 1st visit ] [ Designated as safety issue: No ]
  • To record the drugs used in the treatment of patients diagnosed with hypertension. [ Time Frame: Visits 1-3 ] [ Designated as safety issue: No ]

Enrollment: 1514
Study Start Date: February 2011
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Detailed Description:



Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary hypertensive patients


Inclusion Criteria:

  • Newly diagnosed essential hypertension patients will be eligible for the study.
  • Average of two or more systolic BP readings ≥ 140mmHg or diastolic BP readings ≥ 90mmHg

Exclusion Criteria:

  • History of coronary artery disease
  • History of diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01295021

  Show 99 Study Locations
Sponsors and Collaborators
Principal Investigator: Dr T.N.C. Padmanabhan Dr. Padmanabhan Heart Clinic
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT01295021     History of Changes
Other Study ID Numbers: NIS-CIN-DUM-2010/2
Study First Received: February 3, 2011
Last Updated: June 7, 2013
Health Authority: India: Drugs Controller General of India

Keywords provided by AstraZeneca:
The prevalence of sympathetic overactivity in hypertensive patients.

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases processed this record on November 27, 2014